Medullary Thyroid Carcinoma
Biology, management, and treatment of sporadic and hereditary MTC
Buch in deiner Nähe kaufen
Beschreibung
After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists.
Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC.
This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists.
Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC.
This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
Provides a comprehensive overview of medullary thyroid carcinoma Explains the use of thyroidectomy and tyrosine kinase inhibitors Written by experts in the field
Autor*in
Friedhelm Raue
Themen in »Medullary Thyroid Carcinoma«
Calcitonin Multiple Endocrine Neoplasia Type 2 Pheochromocytoma primary hyperparathyroidism tyrosinekinase inhibitor